fludeoxyglucose f 18 pet imaging in determining protein and gene expression signatures in patients with premalignant polyps or colon cancer

Conditions: Colorectal Cancer; Neoplasm of Uncertain Malignant Potential

Summary: rationale: diagnostic imaging procedures, such as fludeoxyglucose f 18 pet, may be effective in detecting cancer or recurrence of cancer, or premalignant polyps. purpose: this clinical trial is studying fludeoxyglucose f 18-pet imaging to see how well it works in determining protein and gene expression signatures in patients with premalignant polyps or colon cancer.

objectives: primary * to determine the feasibility of ex-vivo imaging of colon cancer and colon polyps using fludeoxyglucose f 18 positron emission tomography (fdg pet). * to evaluate the differences in molecular and genetic profiles between fdg-positive polyps and fdg-negative polyps to suggest what gene mutations and abnormal mrna and/or protein expressions may be required for fdg avidity ("signature" for fdg avidity). secondary * to evaluate the differences in molecular and genetic profiles between fdg-positive polyps and fdg-positive cancers to suggest what gene mutations and abnormal mrna and/or protein expressions may be required for cancer formation ("signature" for cancer). * to evaluate the differences in molecular and genetic profiles between normal colonic mucosa, polyps, and cancer. * to evaluate the differences and similarities in molecular and genetic profiles between fdg-positive cancers and polyps. outline: part i: patients receive fludeoxyglucose f 18 (fdg) iv followed 45-60 minutes later by surgery to remove part or all of the colon. tissue samples of the colon undergo positron emission tomography (pet) imaging. part ii: tissue samples are analyzed for glucose transporters proteins (glut-1, 2, 3, 4, 5, 7) via ihc; presence of k-ras mutation (invariable mutant site on codon 12, 13) via pcr; 18q deletion via fluorescence in situ hybridization (fish) or dcc ihc; mct-1, hex-1, hex-2, and cox-2 expression levels via quantitative rt-pcr method or western blot; apc mutation via pcr- in vitro synthesized-protein assay or rt-pcr direct sequencing method; p53 mutation detection via immunochemistry, rt-pcr direct sequence methods, and western blot; methylation alteration of mgmt, cdkn2a, hltf, mlh1, timp3, hif1, bnip3, and hrk via methylation detecting microchip; and specific gene methylations via methylation-specific pcr. some tissue samples may be saved and banked for future studies.

Eligibility criteria:
subject inclusion criteria: * patients eligible for entry into the study are those: * age 15 to 100 * undergoing resection of a non-sarcomatous primary colon neoplasm who also has 2 or more adenomas each greater than or equal to 7-10mm in size which are anticipated to be removed with the colon specimen. * it will be known from mskcc or outside studies (barium enema, endoscopy, pet/ct, or ct colonography) that the patient has at least 2 proven adenomas 7-10 mm or greater and a primary colon neoplasm subject exclusion criteria: * insulin-dependent diabetics (as established by routine history and presurgical laboratory tests).

Keywords: neoplasm of uncertain malignant potential colon cancer